Drugs that contain Morphine Sulfate

1. Drug name - ARYMO ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899 ZYLA Abuse deterrent pharmaceutical compositions for controlled release Jul, 2033

(10 years from now)

US9044402 ZYLA Abuse-deterrent pharmaceutical compositions for controlled release Jul, 2033

(10 years from now)

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
60MG TABLET, EXTENDED RELEASE;ORAL Discontinued

2. Drug name - MORPHABOND ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314788 DAIICHI SANKYO INC Pharmaceutical compositions configured to deter dosage form splitting Aug, 2028

(5 years from now)

US7955619 DAIICHI SANKYO INC Abuse resistant drugs, method of use and method of making Aug, 2028

(5 years from now)

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
60MG TABLET, EXTENDED RELEASE;ORAL Discontinued
100MG TABLET, EXTENDED RELEASE;ORAL Discontinued

3. Drug name - MORPHINE SULFATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192608 FRESENIUS KABI USA Morphine formulations Mar, 2034

(11 years from now)

US9072781 FRESENIUS KABI USA Morphine formulations Mar, 2034

(11 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs Mar, 2034

(11 years from now)

Treatment: Management of chronic pain in patients requiring opioid analgesia; treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
2MG/ML (2MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
4MG/ML (4MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
5MG/ML (5MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
8MG/ML (8MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription
10MG/ML (10MG/ML) SOLUTION;INTRAMUSCULAR, INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.